Tools   Select Another Resource Report Type

http://www.rand.org/labor/FLS/IFLS.html

A dataset of an on-going multi-level longitudinal survey in Indonesia that collects extensive information on socio-economic and demographic characteristics of respondents, as well as extremely comprehensive interviews with local leaders about community services and facilities. The survey is ideally suited for research on topics related to important dynamic aging processes such as the transition from self-sufficiency to dependency, the decline from robust health to frailty, labor force and earning dynamics, wealth accumulation and decumulation, living arrangements and intergenerational transfers. The first wave of IFLS was fielded in 1993 and collected information on over 30,000 individuals living in 7,200 households. The sample covers 321 communities in 13 provinces in Indonesia and is representative of about 83% of the population. These households were revisited in 1997 (IFLS2), 2000 (IFLS3), and 2007-8 (IFLS4). A 25% sub-sample of households was re-interviewed in 1998 (IFLS2+). Special attention is paid to the measurement of health, including the measurement of anthropometry, blood pressure, lung capacity, a mobility test and collection of dry blood spots by a nurse or doctor. In addition to comprehensive life history data on education, work, migration, marriage and child bearing, the survey collects very detailed information on economic status of individuals and households. Links with non co-resident family members are spelled out in conjunction with information on borrowing and transfers. Information is gathered on participation in community activities and in public assistance programs. Measurement of health is a major focus of the survey. In addition to detailed information about use of private and public health services along with insurance status, respondents provide a self-reported assessment of health status. Detailed information on the local economy and prices of goods and services are also collected. These data may be matched with the individual and household-level data. Considerable attention has been placed on minimizing attrition in IFLS. In each re-survey, about 95% of households have been re-contacted. Around 10-15% of respondents have moved from the location in which they were interviewed in the previous wave. In addition, individuals who split-off from the original households have been followed. They have added around 1,000 households to the sample in 1997 and about 3,000 households in 2000. Data Availability: IFLS1 data are available through ICPSR as study number 6706. Data from subsequent waves of the IFLS can be accessed from the RAND project Website. * Dates of Study: 1993-2008 * Study Features: Longitudinal, International, Anthropometric Measures, Biomarkers * Sample Size: ** 1993: 22,000 (IFLS1) ** 1997: 33,000 (IFLS2) ** 1998: 10,000 (IFLS2+) ** 2000: 37,000 (IFLS3) ** 2008: 44,103 (IFLS4) Links: * IFLS1 ICPSR: http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/06706 * IFLS ICPSR: http://www.icpsr.umich.edu/icpsrweb/ICPSR/studies/00184

Proper citation: Indonesia Family Life Survey (RRID:SCR_005695) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29358&a=31596&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. So far there is only limited knowledge about possible genetic influences in acute spinal cord injuries (SCI). In this project DNA is collected prospectively from persons with SCI admitted to the acute SCI rehabilitation unit of the Karolinska University Hospital. Trauma is the cause of injury in a majority of the patients. Other causes of injury are spinal abscesses, tumors or spinal infarctions. The aim of the project is to create a sufficiently large DNA biobank with samples from 200-400 individuals from clinically well characterized patients to allow for studies of association between candidate genes and clinical outcome parameters.

Proper citation: KI Biobank - SCI (RRID:SCR_005849) Copy   

•   Source: SciCrunch Registry

http://www.knhi.zks.uni-leipzig.de/en/Research/SP03/

The goal of this project is the creation of an extensive biomaterials bank. Materials (blood, serum, plasma, DNA) from all patients who participate in studies in the network will be collected for this purpose. The objective is a consistently high quality standard for the processing, storage and management of all samples. The biomaterials bank is an investment in the future by the network. It enables the competence network and the research community in general to acquire new scientific knowledge about the development, progression and prognosis of the different forms of heart failure. Each time a patient is documented in a study in the competence network, blood (EDTA whole blood and serum) is drawn from the patient, sent by post to the central biomaterials bank and processed there in the central incoming sample laboratory according to specified standards. In the first two subsidization periods, a total of 100,000 samples from approximately 10,000 patients was documented and processed (aliquoting, DNA extraction). These samples are stored in climate-controlled rooms used especially for this purpose at the biomaterial bank of the Experimental and Clinical Research Center (ECRC) in Berlin-Buch at temperatures between -20 and -80 degrees C. As the central infrastructure project for all samples, the biomaterials bank is deeply involved in the networking. There are also intensive collaborations with other competence networks (e.g. the Competence Network for Congenital Heart Defects) and biobanks. The biomaterial bank of the Heart Failure Competence Network also participates in domestic and European pilot projects for networking biomaterial banks (BBMRI, ESFRI, etc.). The goal of these projects is to develop uniform methods for sample processing and use.

Proper citation: Central Biomaterial Bank - German Heart Failure Network (RRID:SCR_004667) Copy   

•   Source: SciCrunch Registry

http://www.interpore.com/

Biomet and Interpore Cross are on the cutting edge of technology in the orthopedic biomaterials market. Our focus is developing and providing truly innovative products, which meet the rapidly expanding needs of orthopedic surgeons both today and in the future. Our Pro Osteon resorbable bone graft material is derived from an abundant non-decorative coral. Pro Osteon is available in a selection of fully resorbable sterile granules and blocks, in a variety of shapes and sizes. Our InterGro DBM products combine the osteoinductivity of DBM with a natural, non-soluble carrier that won''t wash away, delivering a unique bone graft that offers superior handling and performance characteristics. This highly-moldable composite graft can be easily formed to fit any shape fracture or defect.

Proper citation: Interpore Cross International (RRID:SCR_004776) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=103566&l=en

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 3rd, 2023. The ICAP - Integrated analysis of prostate cancer study aims at identifying a set of biomarkers with high prognostic value for prostate cancer progression. These biomarkers will be used to customize treatment and to identify patients with high risk of recurrent disease. Sample types: * EDTA whole blood * DNA Number of sample donors: 505 (sample collection completed)

Proper citation: ICAP - Integrated analysis of prostate cancer (RRID:SCR_006035) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=103538&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 23, 2016. Libro-1 is a study with the overall aim to identify prognostic factors for breast cancer. The study comprise women in the Stockholm-Gotland region that were diagnosed with breast cancer between the years 2001-2008. Register data (tumor characteristics and treatment), lifestyle factors and blood samples have been collected from the participants.

Proper citation: LIBRO-1: Individualized prediction and prevention of breast cancer (RRID:SCR_006036) Copy   

•   Source: SciCrunch Registry

http://cancer.case.edu/research/sharedresources/tissue/services/

A combined tissue bank and core facility which provides annotated human tissue samples for research purposes. The facility also offers high quality tissue procurement, tissue microarray, histology, immunohistochemistry, photomicroscopy, and laser capture microdissection services for both human and animal tissues to biomedical investigators conducting non-clinical research studies. The TPHC offers instruction to researchers on how to incorporate human tissue into research activities and how to work within the boundaries of patient confidentiality and other regulatory issues. The purpose of the TPHC is to provide tissue collection and processing services to intramural and extramural researchers studying cancer and other diseases. Normal, diseased, benign and malignant tissues are obtained, and matched normal adjacent tissues and tissues from different organ sites from the same donor can also be provided when available. Tissue samples are prepared according to user-specified protocols and can be fresh in a medium of choice, fixed in formalin, quick frozen in the vapor phase of liquid nitrogen or snap-frozen by plunging the sample into liquid nitrogen. Frozen tissues are held in the vapor phase of the liquid nitrogen. Tissues can also be embedded, cut and mounted on slides, and stained upon request. Tissue Microarray (TMA) services are offered for the design and construction of TMAs meeting specific project needs. Basic demographic data (age, race, gender) and histopathologic data from Surgical Pathology Reports are provided by the TPHC with the tissues.

Proper citation: Case Western Reserve Tissue Procurement and Histology Core Facility (RRID:SCR_005344) Copy   

•   Source: SciCrunch Registry

http://www.procap.ki.se/procap_studie_info.htm

PROCAP is a study of the importance of lifestyle and genetic factors in the progression of localized cancer of the prostate. Our study hypothesis is that the likelihood of disease recurrence of prostate cancer is modified or determined by genetic variation in the human genome and/or lifestyle factors. To be able to test our hypothesis, we are using a large, population-based cohort of men with localized prostate cancer in Sweden, recruited in 1997-2002, from which detailed clinical information and data on progression already have been collected. From this cohort, we are collecting lifestyle data and blood samples from 8,500 men. If men with progressive prostate cancer could be identified on their genetic make-up, they could be given additional therapies targeted specifically at prostate cancer progression or monitored even more frequently so that progressions could be treated even earlier. If lifestyle factors are important, these results have an impact on recommendations given to men with newly diagnosed prostate cancer. In the study, we are asking the study persons to fill in an Internet-based questionnaire focusing on diet and physical activity and we ask them to leave 2 test tubes of blood at their local urologist/health care center. The pilot study has recently been completed and evaluated and the remaining 7,500 men in the cohort will be included during 2007 and 2008. So far, we have a response rate of approximately 85% on the blood samples. The response rate for the questionnaire is approximately 80% (both in the web based and paper based versions combined). Genotyping and analysis will begin in the fall of 2008. Sample types: * EDTA whole blood * Plasma * DNA Number of sample donors: 5492 (sample collection completed)

Proper citation: KI Biobank - PROCAP (RRID:SCR_006038) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/meb/cancer-of-the-prostate-in-sweden-caps

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 3rd,2023. We have completed the recruitment of this population-based prostate cancer case-control study, one of the largest prostate cancer case-control study populations available so far. This study population was recruited in two phases. The inclusion and exclusion criteria were the same for the first (CAPS1) and second phase (CAPS2), except for the timeframe. In total, 3,030 cases and 1,960 controls participated in CAPS donating blood samples and answering a questionnaire during 2001-2003. In addition we have detailed clinical information on all 3,000 cases. With data generated from CAPS we have 25 published papers and 10 manuscripts since 2004. During 2006 we completed a record linkage to the Cause of Death Registry to determine the cause of death for all participants. We could conclude that 347 of the cases in CAPS had died of prostate cancer. The CAPS study has provided data to several new studies on markers on prostate cancer progression. Sample types: * EDTA whole blood * DNA Number of sample donors: 5015 (sample collection completed)

Proper citation: Cancer of the Prostate in Sweden (CAPS) (RRID:SCR_006033) Copy   

•   Source: SciCrunch Registry

http://ki.se/imm/cefalo-studien

Saliva taken from participants in a study investigating the association between environmental exposures and brain tumors in children aged 7-19 years and the interaction between these risk factors and genetic polymorphisms, which may confer susceptibility to effects of exogenous agents. Sample types: * Saliva Number of sample donors: 886 (sample collection completed)

Proper citation: KI Biobank - CEFALO (RRID:SCR_006034) Copy   

•   Source: SciCrunch Registry

https://clinicaltrials.gov/ct2/show/NCT00014001

The NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study was a nationwide public health-focused clinical trial that compared the effectiveness of older (first available in the 1950s) and newer (available since the 1990s) antipsychotic medications used to treat schizophrenia. These newer medications, known as atypical antipsychotics, cost roughly 10 times as much as the older medications. CATIE is the largest, longest, and most comprehensive independent trial ever done to examine existing therapies for this disease. Schizophrenia is a brain disorder characterized by hallucinations, delusions, and disordered thinking. The course of schizophrenia is variable, but usually is recurrent and chronic, often causing severe disability. Previous studies have shown that taking antipsychotic medications consistently is far more effective than taking no medicine and that the drugs are necessary to manage the disease. The aim of the CATIE study was to determine which medications provide the best treatment for schizophrenia. Additional information may be found by following the links, http://www.nimh.nih.gov/trials/practical/catie/index.shtml, http://www.clinicaltrials.gov/ct/show/NCT00014001?order=1

Proper citation: CATIE - Clinical Antipsychotic Trials in Intervention Effectiveness (RRID:SCR_005615) Copy   

•   Source: SciCrunch Registry

http://www.udel.edu/Biology/Wags/histopage/colorpage/cne/cne.htm

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 13,2026. An image collection of tissue from the central nervous system and peripheral nervous system.

Proper citation: Nervous Tissue Color Images (RRID:SCR_002416) Copy   

•   Source: SciCrunch Registry

http://www.neuroskills.com/

A topical portal and providers of brain injury rehabilitation services. Resources * Pharmacology Guide * Glossary of Brain Injury Terms * Brain Injury Research Articles * Common Brain Injury Assessment Tools / Rating Scale * Certified Continuing Education Courses * Links to Resource Sites

Proper citation: Centre for Neuro Skills (RRID:SCR_006106) Copy   

•   Source: SciCrunch Registry

http://phenotips.cs.toronto.edu/

A software tool providing a Web interface and a database back-end for collecting clinical symptoms and physical findings observed in patients with genetic disorders. The main goals of this software are * To allow for collecting patient data in standard formats, enabling effortless data exchange and automated search in annotated gene and disease databases, and * To provide advanced functionalities and a friendly user interface that help reduce the clinician''''s workload, permitting seamless use of this application within the clinician''''s routine. PhenoTips uses the Human Phenotype Ontology (HPO) to express clinical phenotypes, and provides a friendly interface with error-tolerant, predictive search of phenotypic descriptions. PhenoTips closely mirrors clinician workflows: observations can be recorded directly during the patient encounter, and the interface is compatible with any device that runs a modern Web browser. The clinician can record demographic information, family history, medical history, various standard measurements, phenotypic abnormalities detected in the patient, pertinent indications that were not observed and that can be helpful for differential diagnosis, relevant images depicting manifestations of the patient''''s disorders, and additional notes for each of these categories. The software automatically plots growth curves, selects phenotypes reflecting abnormal measurements, instantly finds OMIM disorders matching the phenotypic description and suggests other symptoms to investigate in order to reach a more accurate diagnosis.

Proper citation: PhenoTips (RRID:SCR_006340) Copy   

•   Source: SciCrunch Registry

http://www.sph.umich.edu/csg/abecasis/GOLD/

Software package that provides a graphical summary of linkage disequilibrium in human genetic data. The graphical summary is well suited to the analysis of dense genetic maps, where contingency tables are cumbersome to interpret. An interface to the Simwalk2 application allows for the analysis of family data.

Proper citation: Graphical Overview of Linkage Disequilibrium (RRID:SCR_007151) Copy   

•   Source: SciCrunch Registry

http://www.ncri.org.uk/ccb/index.html

The Confederation of Cancer Biobanks (CCB) is a consortium of organisations based in the UK that are involved in the development, management and use of biobank resources for cancer research. The Confederation aims to promote and disseminate a collective view on best practices for biobanks and to promote transfer of knowledge and experiences between banks. While individual banks retain their full autonomy, membership leads to mutual benefit, ensures complementarities, avoids unnecessary competition and ensures a coordinated approach to cancer biosample provision. This will benefit all involved by allowing the sharing of expertise and information, the establishment of harmonized standards for the operation of cancer biobanks and provide a means to access a larger pool of biosamples from the confederated banks. The initial achievements of the NCRI Confederation of Cancer Biobanks were the drafting of a Memorandum of Understanding for the founder members of the Confederation, and a document outlining the Guiding Principles for the management and operation of a tissue bank / biobank in the contemporary ethical and legal setting. Any organization based in the UK, which collects and distributes biosamples for cancer research (not necessarily in the UK), may apply to join. CCB Members receive: * access to the Members Area of the web site containing shared resources * inclusion in email discussion fora with other members * networking opportunities with other members * inclusion in a collective voice to research funders, policy makers, legislators and others * inclusion in the NCRI''s new on-line sample directory * one free registration for each CCB workshop * a future opportunity to pursue accreditation/quality endorsement for the bank * a potential future opportunity for your donors to join a donor forum, which provides patients/sample donors with a mechanism of keeping in touch with research biobanking activities.

Proper citation: Confederation of Cancer Banks (RRID:SCR_006885) Copy   

•   Source: SciCrunch Registry

http://www.alz.washington.edu/

A clinical research, neuropathological research and collaborative research database that uses data collected from 29 NIA-funded Alzheimer's Disease Centers (ADCs). The database consists of several datasets, and searches may be done on the entire database or on individual datasets. Any researcher, whether affiliated with an ADC or not, may request a data file for analysis or aggregate data tables. Requested aggregate data tables are produced and returned as soon as the queue allows (usually within 1-3 days depending on the complexity).

Proper citation: National Alzheimer's Coordinating Center (RRID:SCR_007327) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/nia/

A cell repository containing cells and DNA for studies of aging and the degenerative processes associated with it. Scientists use the highly-characterized, viable, and contaminant-free cell cultures from this collection for research on such diseases as Alzheimer's disease, progeria, Parkinson's disease, Werner syndrome, and Cockayne syndrome. The collections of the Repository include DNA and cell cultures from individuals with premature aging disorders, as well as DNA from individuals of advanced age from the the Baltimore Longitudinal Study of Aging at the Gerontology Research Center and other Longevity Collections. The Repository also includes samples from an Adolescent Study of Obesity, Apparently Healthy Controls, Animal Models of Aging, and both human and animal differentiated cell types. The cells in this resource have been collected over the past three decades using strict diagnostic criteria and banked under the highest quality standards of cell culture. Scientists can use the highly-characterized, viable, and contaminant-free cell cultures from this collection for genetic and cell biology research.

Proper citation: Aging Cell Repository (RRID:SCR_007320) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=103697&l=en

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 3rd,2023. Recently it has been discovered that specific Single Nucleotide Polymorphisms (SNPs) may elevate the risk of developing prostate cancer. This study aims at investigating whether it is possible to use these SNPs in a clinical setting in order to sharpen the diagnostic tools when investigating if a man has prostate cancer. By collecting blood from men who have undergone a needle biopsy of the prostate and do a SNP analysis of their genes and compare this with the result of the biopsy and PSA result we hope to be able to develop a test that is more specific than the routine that is being used today. Sample types: * EDTA whole blood * DNA Number of sample donors: 5321 (June 2010)

Proper citation: SPSAC - Stockholm PSA Cohort (RRID:SCR_006042) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29346&a=103574&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented September 2, 2016. Cardiovascular disease and periodontitis are common diseases, causing considerable suffering and costs. Despite strong links between the two diseases it is unclear if periodontitis causes cardiovascular disease. The primary aims are to investigate whether periodontitis is a risk factor for the development of myocardial infarction and if periodontitis increases the risk for new cardiovascular events such as myocardial infarction, stroke and death in patients with a previous myocardial infarction. PAROKRANK is a case control study. Cases (n=1500) are patients with a first myocardial infarction and controls population derived people without cardiovascular disease(n=1500). Both groups are subjected to predefined dental examinations, analyses of a variety of risk factors and a biobank of blood and dental samples will be established. Information is collected from available registries (RIKS-HIA and SEPHIA) and study specific records.

Proper citation: KI Biobank - PAROKRANK (RRID:SCR_006045) Copy   

•   Source: SciCrunch Registry